Bristol Myers Squibb to invest in New Cell Therapy Manufacturing facility in Massachusetts, USA

Specifications:

Name:

Bristol Myers Squibb to invest in New Cell Therapy Manufacturing facility in Massachusetts, USA

Location:

Devens, Massachusetts

Company:

Bristol Myers Squibb

Estimated Cost:

-

Source:

bms.com

Introduction:

Construction is underway for a new cell therapy manufacturing facility in Devens, Mass., a part of Bristol Myers Squibb’s significant investment to support clinical and commercial manufacturing.

Features:

The Devens site is the latest investment from Bristol Myers Squibb as the company expands its robust global manufacturing network. The 244,000 square foot facility adds to the company’s already established state-of-the-art cell therapy manufacturing network with cutting-edge technologies and highly trained manufacturing teams. The Devens site will be equipped to enable quick ramp up of capacity for clinical and commercial cell therapy products.

Manufacturing cell therapies is both operationally and technically complex because they are manufactured uniquely for each individual patient, using a patient’s own T cells as the starting material. Each batch of engineered T cells is made for infusion back to the original cancer patient, and it is critical for companies to develop reliable quality supply, and rapid turnaround time.

The new cell therapy facility will be located on Bristol Myers Squibb’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine. The new cell therapy facility allows accelerated career development for current and prospective employees across biologics and cell therapies on a single campus, with employees having access to all existing campus amenities.

The Devens campus is part of Bristol Myers Squibb’s growing presence in Massachusetts. BMS also operates two R&D facilities in Cambridge, MA and will be bringing those two sites together into a new building at Cambridge Crossing in 2023.